GXO Logistics Inc vs Nuwellis Inc — how do they compare? GXO Logistics Inc trades at $46.42 (market cap $5.32B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: GXO Logistics Inc is far larger — about 2418.2× Nuwellis Inc's market cap, and GXO Logistics Inc is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GXO Logistics Inc for 28 Days and Nuwellis Inc for 26 Days on average.
| GXO | NUWE | |
|---|---|---|
Market Cap | $5.32B | $2.20M |
Volume | 1,255,816 | 121,544 |
Sector | Industrials | Health |
52-Week High | $65.59 | $146.65 |
52-Week Low | $44.17 | $0.68 |
Typical Hold Time | 28 Days | 26 Days |
Enterprise Value | $10.67B | -$1.52M |
Signals from Pluang's Aura AI — not financial advice
GXO trades at $46.58, up 1.28% today, with a neutral technical signal and strong analyst support. The company reported three consecutive quarterly EPS beats and is expanding through strategic partnerships, including a new 10-year logistics deal with Columbia Sportswear in Europe. Revenue grew to $13.18B in 2025, with a net income margin of 0.96%, though valuation metrics like a P/E of 41.03 appear elevated relative to profitability.
The outlook is positive, driven by operational improvements and industry tailwinds, but risks include margin pressures and high debt. With an 89% buy rating from analysts and a consensus price target of $66.67, the stock offers significant upside potential if execution aligns with growth initiatives.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.
Read more on GXO →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →